Advertisement

Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials

  • Ling Li
    Affiliations
    Department of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China
    Search for articles by this author
  • Zhanyu Pan
    Correspondence
    Address for correspondence: Zhanyu Pan, MD, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Rd, Hexi District, Tianjin, China 300060
    Affiliations
    Department of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China
    Search for articles by this author

      Abstract

      Background

      Progression-free survival (PFS) and time to progression (TTP) have been reported to correlate with overall survival (OS) in several cancer types. To our knowledge, however, the correlation between them is unclear.

      Methods

      A literature-based meta-analysis was performed to assess whether PFS and TTP can be considered reliable surrogate end points for OS in a phase 3 clinical trial of advanced breast cancer (ABC). The median hazard ratios of PFS/TTP and OS were analyzed by determining their nonparametric Spearman rank correlation coefficients (Rs).

      Results

      A total of 37 trials with 38 treatment arms and 14,966 patients were selected for analysis. The Rs between the median PFS/TTP and OS was 0.405 (95% confidence interval [CI], 0.191-0.582; P = .003), and the correlation coefficient between the hazard ratios of PFS/TTP and OS was 0.555 (95% CI, 0.277-0.748; P = .003). PFS/TTP was closely correlated with OS in the trials of targeted therapy-based treatment (Rs = 0.872; 95% CI, 0.619-0.962; P = .0001) and of PFS/TTP or OS benefit (Rs = 0.753 and Rs = 0.821, respectively) for ABC.

      Conclusions

      Both PFS and TTP can be considered valid surrogate end points for OS in the trials of targeted therapy-based treatments and clinical benefits for ABC. Further research is necessary to clarify the surrogacy of PFS/TTP for OS in other trials of targeted therapy-based treatments for ABC.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Giordano S.H.
        • Buzdar A.U.
        • Smith T.L.
        • et al.
        Is breast cancer survival improving?.
        Cancer. 2004; 100: 44-52
        • Chul K.
        • Vinay P.
        Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs.
        Mayo Clin Proc. 2016; ([e pub ahead of print])
        • Tierney J.F.
        • Stewart L.A.
        • Ghersi D.
        • et al.
        Practical methods for incorporating summary time-to-event data into meta-analysis.
        Trials. 2007; 8: 16
        • Paridaens R.
        • Biganzoli L.
        • Bruning P.
        • et al.
        Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over.
        J Clin Oncol. 2000; 18: 724-733
        • Namer M.
        • Soler-Michel P.
        • Turpin F.
        • et al.
        Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.
        Eur J Cancer. 2011; 37: 1132-1140
        • Ejlertsen B.
        • Mouridsen H.T.
        • Langkjer S.T.
        • et al.
        Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
        J Clin Oncol. 2004; 22: 2313-2320
        • Jassem J.
        • Pieńkowski T.
        • Płuzańska A.
        • et al.
        Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
        J Clin Oncol. 2001; 19: 1707-1715
        • Biganzoli L.
        • Cufer T.
        • Bruning P.
        • et al.
        Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
        J Clin Oncol. 2002; 20: 3114-3121
        • Chan S.
        • Davidson N.
        • Juozaityte E.
        • et al.
        Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
        Ann Oncol. 2004; 15: 1527-1534
        • Langley R.E.
        • Carmichael J.
        • Jones A.L.
        • et al.
        Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
        J Clin Oncol. 2005; 23: 8322-8330
        • Bontenbal M.
        • Creemers G.J.
        • Braun H.J.
        • et al.
        Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
        J Clin Oncol. 2005; 23: 7081-7088
        • Pacilio A.
        • Morabito A.
        • Nuzzo F.
        • et al.
        Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.
        Br J Cancer. 2006; 94: 1233-1236
        • Cassier P.A.
        • Chabaud S.
        • Trillet-Lenoir V.
        • et al.
        A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
        Breast Cancer Res Treat. 2008; 109: 343-350
        • Blohmer J.-U.
        • Schmid P.
        • Hilfrich J.
        • et al.
        Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
        Ann Oncol. 2010; 21: 1430-1435
        • Joensuu H.
        • Sailas L.
        • Alanko T.
        • et al.
        Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
        Ann Oncol. 2010; 21: 968-973
        • Mavroudis D.
        • Papakotoulas P.
        • Ardavanis A.
        • et al.
        Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as firstline treatment in women with advanced breast cancer.
        Ann Oncol. 2010; 21: 48-54
        • Hatschek T.
        • Carlsson L.
        • Einbeigi Z.
        • et al.
        Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
        Breast Cancer Res Treat. 2012; 131: 939-947
        • Lück H.-J.
        • Du Bois A.
        • Loibl S.
        • et al.
        Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
        Breast Cancer Res Treat. 2013; 139: 779-787
        • Nabholtz J.M.
        • Falkson C.
        • Campos D.
        • et al.
        Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
        J Clin Oncol. 2003; 21: 968-975
        • Lorusso V.
        • Giotta F.
        • Bordonaro R.
        • et al.
        Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: a multicenter phase III study.
        Int J Oncol. 2014; 45: 2137-2142
        • Takashima T.
        • Mukai H.
        • Hara F.
        • et al.
        Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
        Lancet Oncol. 2016; 17: 90-98
        • Smorenburg C.H.
        • deGroot S.M.
        • vanLeeuwen-Stok A.E.
        • et al.
        A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
        Ann Oncol. 2014; 25: 599-605
        • Milla-Santos A.
        • Milla L.
        • Rallo L.
        • et al.
        Phase III randomized trial of toremifene vs. tamoxifen in hormone-dependent advanced breast cancer.
        Breast Cancer Res Treat. 2001; 65: 119-124
        • Mouridsen H.
        • Gershanovich M.
        • Sun Y.
        • et al.
        Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
        J Clin Oncol. 2003; 21: 2101-2109
        • Paridaens R.J.
        • Dirix L.Y.
        • Beex L.V.
        • et al.
        Phase III Study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
        J Clin Oncol. 2008; 26: 4883-4890
        • Mouridsen H.T.
        Letrozole in advanced breast cancer: the PO25 trial.
        Breast Cancer Res Treat. 2007; 105: 19-29
        • Mehta R.S.
        • Barlow W.E.
        • Albain K.S.
        • et al.
        Combination anastrozole and fulvestrant in metastatic breast cancer.
        N Engl J Med. 2012; 367: 435-444
        • Sparano J.A.
        • Bernardo P.
        • Stephenson P.
        • et al.
        Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196.
        J Clin Oncol. 2004; 22: 4683-4690
        • Nicholas R.
        • Leyland-Jones B.
        • Asmar L.
        • et al.
        Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
        J Clin Oncol. 2006; 24: 2786-2792
        • Valero V.
        • Forbes J.
        • Pegram M.D.
        • et al.
        Phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 Study): two highly active therapeutic regimens.
        J Clin Oncol. 2011; 29: 149-156
        • Andersson M.
        • Lidbrink E.
        • Bjerre K.
        • et al.
        Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–positive breast cancer: the HERNATA Study.
        J Clin Oncol. 2011; 29: 264-271
        • Di Leo A.
        • Gomez H.L.
        • Aziz A.
        • et al.
        Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
        J Clin Oncol. 2008; 26: 5544-5552
        • Guan Z.
        • Xu B.
        • DeSilvio M.L.
        • et al.
        Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer.
        J Clin Oncol. 2013; 31: 1947-1953
        • Baselga J.
        • Manikhas A.
        • Cortés J.
        • et al.
        Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
        Ann Oncol. 2014; 25: 592-598
        • Bergh J.
        • Bondarenko I.M.
        • Lichinitser M.R.
        • et al.
        First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
        J Clin Oncol. 2012; 30: 921-929
        • Martín M.
        • Loibl S.
        • von Minckwitz G.
        • et al.
        Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the Letrozole/Fulvestrant and Avastin (LEA) Study.
        J Clin Oncol. 2015; 33: 1045-1052
        • Rugo H.S.
        • Barry W.T.
        • Moreno-Aspitia A.
        • et al.
        Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound Nab-Paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance).
        J Clin Oncol. 2015; 33: 2361-2369
        • Mackey J.R.
        • Ramos-Vazquez M.
        • Lipatov O.
        • et al.
        Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
        J Clin Oncol. 2015; 33: 141-148
        • Swain S.M.
        • Baselga J.
        • Kim S.-B.
        • et al.
        Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
        N Engl J Med. 2015; 372: 724-734
        • Lück H.-J.
        • Lübbe K.
        • Reinisch M.
        • et al.
        Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
        Breast Cancer Res Treat. 2015; 149: 141-149
        • Sherrill B.
        • Amonkar M.
        • Wu Y.
        • et al.
        Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.
        Br J Cancer. 2008; 99: 1572-1578
        • Buyse M.
        • Burzykowski T.
        • Carroll K.
        • et al.
        Progression-free survival is a surrogate for survival in advanced colorectal cancer.
        J Clin Oncol. 2007; 25: 5218-5224
        • Foster N.R.
        • Qi Y.
        • Shi Q.
        • et al.
        Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
        Cancer. 2011; 117: 1262-1271
        • Shitara K.
        • Ikeda J.
        • Yokota T.
        • et al.
        Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.
        Invest New Drugs. 2012; 30: 1224-1231
        • Sherrill B.
        • Kaye J.A.
        • Sandin R.
        • et al.
        Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.
        Onco Targets Ther. 2012; 5: 287-296
        • Burzykowski T.
        • Buyse M.
        • Piccart-Gebhart M.J.
        • et al.
        Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
        J Clin Oncol. 2008; 26: 1987-1992
        • Michiels S.
        • Le Maitre A.
        • Buyse M.
        • et al.
        Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
        Lancet Oncol. 2009; 10: 341-350
        • D'Amico A.V.
        • Chen M.H.
        • de Castro M.
        • et al.
        Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.
        Lancet Oncol. 2012; 13: 189-195